Published mark
Vir Biotechnology, Inc.
NASDAQ: VIR. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:ea6765c2-1439-4f2f-adb3-5181ccaae732
- SEC CIK
- 0001706431
- Record version
- vpublic-1:ro-d751713988987e9331980363e24189ce, published Oct 27, 2026
- Newest evidence
- Apr 16, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Marianne De BackerSince Feb 23, 2026
- Chair
- Not published
- Independent
- 0 / 17 directors published
- Published claims
- 313 distinct sources
- Evidence records
- 70 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 7 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
EXECUTIVE APPOINTED
Brent Sabatini executive of Vir Biotechnology, Inc., effective 2026-02-23.
EffectiveEffective Feb 23, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Senior Vice President, Finance and Chief Accounting Officer | Brent Sabatini | Feb 2026 | current | Source reportedE3 |
| Executive Vice President and Chief Financial Officer | Jason O'Byrne | Feb 2026 | current | Source reportedE4 |
| Chief Executive Officer and Director | Marianne De Backer | Feb 2026 | current | Source reportedE5 |
| General Counsel | Vanina de Verneuil | Feb 2026 | current | Source reportedE6 |
Board of directors
Evidence7 directors published. 0 of 1 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Elliott Sigal | Independence not published | 2020 | Compensation CommitteeScience and Technology Committee, chair | Source reportedE2 |
| Janet Napolitano | Independence not published | 2020 | Compensation CommitteeNominating and Corporate Governance Committee | Source reportedE2 |
| Jeffrey S. Hatfield | Independence not published | 2020 | Audit CommitteeNominating and Corporate Governance Committee, chair | Source reportedE2 |
| Marianne De Backer | Not independent | 2023 | None published | Source reportedE2 |
| Norbert Bischofberger | Independence not published | 2024 | Compensation CommitteeScience and Technology Committee | Source reportedE2 |
| Ramy Farid | Independence not published | 2024 | Audit CommitteeScience and Technology Committee | Source reportedE2 |
| Robert More | Independence not published | 2016 | Audit CommitteeCompensation Committee, chair | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit Committee | Not published | Jeffrey S. Hatfield, Ramy Farid, Robert More | Not described in the published record |
| Compensation Committee | Robert More | Robert More, Elliott Sigal, Janet Napolitano, Norbert Bischofberger | Not described in the published record |
| Nominating and Corporate Governance Committee | Jeffrey S. Hatfield | Jeffrey S. Hatfield, Janet Napolitano | Not described in the published record |
| Science and Technology Committee | Elliott Sigal | Elliott Sigal, Norbert Bischofberger, Ramy Farid | Not described in the published record |
Committee RecordAudit Committee: Chair not stated; Members Jeffrey S. Hatfield; Ramy Farid; Robert More
Committee AppointmentJeffrey S. Hatfield: member, Audit Committee
Committee AppointmentRamy Farid: member, Audit Committee
Committee AppointmentRobert More: member, Audit Committee
Committee RecordCompensation Committee: Chair Robert More; Members Robert More (Chair); Elliott Sigal; Janet Napolitano; Norbert Bischofberger
Committee AppointmentRobert More: chair, Compensation Committee
Committee AppointmentElliott Sigal: member, Compensation Committee
Committee AppointmentJanet Napolitano: member, Compensation Committee
Committee AppointmentNorbert Bischofberger: member, Compensation Committee
Committee RecordNominating and Corporate Governance Committee: Chair Jeffrey S. Hatfield; Members Jeffrey S. Hatfield (Chair); Janet Napolitano
Committee AppointmentJeffrey S. Hatfield: chair, Nominating and Corporate Governance Committee
Committee AppointmentJanet Napolitano: member, Nominating and Corporate Governance Committee
Committee RecordScience and Technology Committee: Chair Elliott Sigal; Members Elliott Sigal (Chair); Norbert Bischofberger; Ramy Farid
Committee AppointmentElliott Sigal: chair, Science and Technology Committee
Committee AppointmentNorbert Bischofberger: member, Science and Technology Committee
Committee AppointmentRamy Farid: member, Science and Technology Committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerMarianne De Backer, Chief Executive Officer and Director, from Feb 23, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingVIR (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 27, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameVir Biotechnology, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Brent SabatiniSenior Vice President, Finance and Chief Accounting Officercompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:12
- Jason O'ByrneExecutive Vice President and Chief Financial Officercompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:13
- Marianne De BackerChief Executive Officer and Directorcompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:14, company:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:8
- Vanina de VerneuilGeneral Counselcompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:15
- Elliott SigalDirectorcompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:5
- Janet NapolitanoDirectorcompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:6
- Jeffrey S. HatfieldDirectorcompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:7
- Norbert BischofbergerDirectorcompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:9
- Ramy FaridDirectorcompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:10
- Robert MoreDirectorcompany:ea6765c2-1439-4f2f-adb3-5181ccaae732:leadership_role:11
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 7 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 27, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 16, 2026. Retrieved Sep 2, 2026. Cited by 7 Claims.
- E3sec filing. Published Feb 23, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E4sec filing. Published Feb 23, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E5sec filing. Published Feb 23, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E6sec filing. Published Feb 23, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E7governance_people_committees. sec proxy. Cited by 16 Claims.
What changed in version public-1:ro-d751713988987e9331980363e24189ce
vpublic-1:ro-d751713988987e9331980363e24189ce published Oct 27, 2026- Brent Sabatini executive of Vir Biotechnology, Inc., effective 2026-02-23.
- Jason O'Byrne executive of Vir Biotechnology, Inc., effective 2026-02-23.
- Marianne De Backer executive of Vir Biotechnology, Inc., effective 2026-02-23.
- Vanina de Verneuil executive of Vir Biotechnology, Inc., effective 2026-02-23.
- Norbert Bischofberger seat on Vir Biotechnology, Inc., effective 2024-01-01.
- Ramy Farid seat on Vir Biotechnology, Inc., effective 2024-01-01.
- Marianne De Backer seat on Vir Biotechnology, Inc., effective 2023-01-01.
- Elliott Sigal seat on Vir Biotechnology, Inc., effective 2020-01-01.
- Janet Napolitano seat on Vir Biotechnology, Inc., effective 2020-01-01.
- Jeffrey S. Hatfield seat on Vir Biotechnology, Inc., effective 2020-01-01.
- Robert More seat on Vir Biotechnology, Inc., effective 2016-01-01.